{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:32:02Z","timestamp":1790890322337,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ygyno.2011.01.030","type":"journal-article","created":{"date-parts":[[2011,2,17]],"date-time":"2011-02-17T06:35:50Z","timestamp":1297924550000},"page":"303-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct10101192","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John","family":"Farley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Tate","family":"Thigpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.01.030_bb0005","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","article-title":"Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage 1B cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0010","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0015","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"341","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"issue":"503","key":"10.1016\/j.ygyno.2011.01.030_bb0020","first-page":"e1","article-title":"Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial","volume":"197","author":"Stehman","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0025","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/0002-9378(72)90741-7","article-title":"Exploratory celiotomy for surgical staging of cervical cancer","volume":"113","author":"Averette","year":"1972","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0090-8258(84)90151-3","article-title":"Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study)","volume":"19","author":"Berman","year":"1984","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0035","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/1097-0142(197506)35:6<1510::AID-CNCR2820350605>3.0.CO;2-U","article-title":"Treatment of para-aortic nodes in carcinoma of the cervix","volume":"35","author":"Lepanto","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0040","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0002-9378(77)90633-0","article-title":"Incidence, significance and follow-up of para-aortic lymph node metastases in late invasive carcinoma of the cervix","volume":"128","author":"Nelson","year":"1977","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/1097-0142(197803)41:3<1049::AID-CNCR2820410337>3.0.CO;2-U","article-title":"Influence of exploratory celiotomy on the management of carcinoma of the cervix. A preliminary report","volume":"41","author":"Sudarsanam","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0050","first-page":"2884","article-title":"Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas","volume":"5","author":"Akimoto","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0055","first-page":"2166","article-title":"Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis","volume":"6","author":"Huang","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0060","first-page":"701","article-title":"In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody","volume":"6","author":"Milas","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0065","first-page":"4343","article-title":"Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type 1 protein kinase A antisense oligonucleotide","volume":"6","author":"Bianco","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0070","first-page":"909","article-title":"Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225","volume":"5","author":"Ciardiello","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0075","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2001.19.13.3234","article-title":"Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer","volume":"19","author":"Robert","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0080","first-page":"577","article-title":"Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis","volume":"5","author":"Kersemaekers","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2005.05.045","article-title":"Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix","volume":"99","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0090","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0360-3016(03)00209-8","article-title":"Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy","volume":"56","author":"Gaffney","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/gyno.2002.6803","article-title":"Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma","volume":"87","author":"Kim","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0090-8258(03)00504-3","article-title":"P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma","volume":"91","author":"Cho","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0115","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study","volume":"23","author":"Long","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0120","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"22","author":"Moore","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0125","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0130","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/sim.2139","article-title":"One- and two-stage designs for stratified phase II clinical trials","volume":"24","author":"London","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0135","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0090-8258(89)90540-4","article-title":"Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix","volume":"33","author":"Pfeiffer","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0090-8258(91)90107-G","article-title":"Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement","volume":"40","author":"Hayashi","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/jcp.46.2.149","article-title":"Prognostic value of epidermal growth factor receptor expression in cervical carcinoma","volume":"46","author":"Hale","year":"1993","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.0.CO;2-K","article-title":"Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study","volume":"78","author":"Kristensen","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3835(97)00421-7","article-title":"Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer","volume":"123","author":"Scambia","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0160","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14712590902870394","article-title":"KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue","volume":"9","author":"Silvestris","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0170","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0175","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0180","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/IGC.0b013e3181a13186","article-title":"High-risk human papillomavirus DNA in the primary tumor, sentinel, and nonsentinel pelvic lymph nodes in patients with early-stage cervical cancer: a correlation with histopathology","volume":"19","author":"Slama","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0185","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/ijc.22633","article-title":"Human papillomavirus 16 and head and neck squamous cell carcinoma","volume":"120","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0190","first-page":"3187","article-title":"Human papillomavirus type 16 and squamous cell carcinoma of the head and neck","volume":"8","author":"Ringstr\u00f6m","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0195","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2007.12.7662","article-title":"EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer","volume":"26","author":"Kumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0200","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/jnci\/89.17.1271","article-title":"Expression of epidermal growth factor receptor and human papillomavirus E6\/E7 proteins in cervical carcinoma cells","volume":"89","author":"Hu","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0205","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00018-005-5561-x","article-title":"Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK\/ERK1, 2 and P13K\/Akt","volume":"63","author":"Kim","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0210","first-page":"6139","article-title":"K-ras activation in neoplasms of the human female reproductive tract","volume":"50","author":"Enomoto","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0215","first-page":"5308","article-title":"K-ras activation in premalignant and malignant epithelial lesions of the human uterus","volume":"51","author":"Enomoto","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0220","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1158\/1078-0432.CCR-08-0539","article-title":"Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer","volume":"14","author":"Hirsch","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0225","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2007.14.0111","article-title":"Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy","volume":"26","author":"Hirsch","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.01.030_bb0230","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/IGC.0b013e3181a83467","article-title":"A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"19","author":"Schilder","year":"2009","journal-title":"Int J Gynecol Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:26:17Z","timestamp":1758770777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0090825811000746"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.01.030","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}